Latest Conference Articles

Jonathan D. Shader, DO, CPA, presents a case study involving an uncommon cause of posterior-intermediate uveitis: the black ink used to create a tattoo.

Case study looks at a 90-year-old patient with a sebaceous gland carcinoma with corneal and bulbar conjunctival involvement, but the eyelid was spared.

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Case study of 2 sisters with Leber’s congenital amaurosis (LCA) analyzes ocular findings, connection.

Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.

This announcement was made at the 2021 ASCRS annual meeting.

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Christopher Starr, MD, discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.

Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Investigators use an adeno-associated viral vector in a clinical trial to deliver a normal functioning copy of the RPGR gene via subretinal injection.

A non-viral gene therapy sustained drug-delivery product that delivers anti-VEGF to the eye may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet AMD.

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Bryce Buchowicz, MD, outlines roadblocks to timely diagnosis of central retinal artery occlusion and treatment with tissue plasminogen activator.

Steffen E. Künzel, MD, discusses the key points of his research presentation regarding low vulnerability of the posterior eye segment to SARS-CoV-2 infection.

During ARVO 2021, Sunil Srivastava, MD, points out that optical coherence tomography characteristics may be predictive of the efficacy of the injections.

At ARVO’s 2021 virtual annual meeting, John Wells, MD, presents efficacy, durability, and safety findings from the phase 3 YOSEMITE and RHINE trials.

Uwe Oberheide, MD, discusses the key findings of his virtual ARVO 2021 presentation on modeling of IOLs for patients with AMD by ray-tracing.

According to Jessica Liu, patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.

Investigators found that non-invasive ocular blood flow measurement using laser speckle flowgraphy may be a new indicator of shock-related organ damage.

Investigators review changes in ocular anterior segment blood flow and temperature after treatment of patients with meibomian gland dysfunction.

Seth Miller, clinical operations manager at Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.